$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-K Financial Statement

#000149315223022936 Filed on June 29, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2023
Revenue	$9.000M	$8.642M	$34.16M
YoY Change	17.3%	12.64%	5.87%
Cost Of Revenue	$4.230M	$5.200M	$17.56M
YoY Change	15.09%	22.15%	0.54%
Gross Profit	$4.751M	$3.441M	$16.59M
YoY Change	18.83%	0.78%	12.16%
Gross Profit Margin	52.78%	39.82%	48.58%
Selling, General & Admin	$1.677M	$799.5K	$5.162M
YoY Change	-2.71%	-48.0%	15.26%
% of Gross Profit	35.29%	23.23%	31.11%
Research & Development	$1.144M	$2.425M	$6.200M
YoY Change	19.69%	228.24%	53.04%
% of Gross Profit	24.07%	70.47%	37.36%
Depreciation & Amortization	$328.3K	$344.1K	$1.278M
YoY Change	10.8%	14.38%	5.67%
% of Gross Profit	6.91%	10.0%	7.7%
Operating Expenses	$3.149M	$3.535M	$12.92M
YoY Change	5.83%	37.94%	32.84%
Operating Profit	$1.602M	-$94.09K	$3.676M
YoY Change	56.65%	-111.05%	-27.51%
Interest Expense	$119.4K	-$469.2K	$1.113M
YoY Change	-44.92%	187.16%	-9.81%
% of Operating Profit	7.45%		30.27%
Other Income/Expense, Net	-$305.3K		$309.9K
YoY Change	-57.41%		-74.88%
Pretax Income	$1.297M	-$856.1K	$3.986M
YoY Change	323.94%	-224.37%	-36.78%
Income Tax	$155.0K	$373.2K	$424.0K
% Of Pretax Income	11.95%		10.64%
Net Earnings	$1.142M	-$1.229M	$3.562M
YoY Change	273.28%	-150.61%	-55.7%
Net Earnings / Revenue	12.69%	-14.22%	10.43%
Basic Earnings Per Share	$0.00		$0.00
Diluted Earnings Per Share	$0.00	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	1.014B shares	1.014B shares	1.013B shares
Diluted Shares Outstanding	1.015B shares		1.013B shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.077M	$7.832M	$7.832M
YoY Change	-54.11%	-8.24%	-8.24%
Cash & Equivalents	$9.077M	$7.832M
Short-Term Investments
Other Short-Term Assets	$998.1K	$1.033M	$1.033M
YoY Change	96.5%	95.99%	95.99%
Inventory	$11.17M	$9.551M	$9.551M
Prepaid Expenses
Receivables	$6.201M	$3.095M	$3.095M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$27.44M	$21.51M	$21.51M
YoY Change	-13.89%	14.04%	14.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.10M	$10.43M	$10.44M
YoY Change	75.47%	75.14%	49.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$21.02K	$21.02K	$21.02K
YoY Change	-92.79%	-77.09%	-77.09%
Other Assets	$2.587M	$2.584M	$2.584M
YoY Change	0.4%	0.29%	0.29%
Total Long-Term Assets	$19.05M	$19.39M	$19.39M
YoY Change	17.34%	19.02%	19.02%
TOTAL ASSETS
Total Short-Term Assets	$27.44M	$21.51M	$21.51M
Total Long-Term Assets	$19.05M	$19.39M	$19.39M
Total Assets	$46.50M	$40.90M	$40.90M
YoY Change	-3.34%	16.35%	16.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.875M	$2.447M	$2.447M
YoY Change	16.15%	70.99%	70.99%
Accrued Expenses	$5.929M	$5.048M	$5.063M
YoY Change	23.28%	7.56%	3.4%
Deferred Revenue	$13.33K	$13.33K
YoY Change	0.0%	0.0%
Short-Term Debt	$4.000M	$0.00	$0.00
YoY Change
Long-Term Debt Due	$251.3K	$310.9K	$310.9K
YoY Change	-42.23%	-12.15%	-12.15%
Total Short-Term Liabilities	$12.08M	$7.834M	$7.834M
YoY Change	70.59%	17.02%	17.02%
LONG-TERM LIABILITIES
Long-Term Debt	$3.578M	$3.562M	$3.562M
YoY Change	-72.91%	156.43%	156.43%
Other Long-Term Liabilities	$726.6K		$540.6K
YoY Change	1691.89%		-70.68%
Total Long-Term Liabilities	$4.305M	$4.102M	$4.102M
YoY Change	-72.22%	26.9%	26.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.08M	$7.834M	$7.834M
Total Long-Term Liabilities	$4.305M	$4.102M	$4.102M
Total Liabilities	$16.38M	$11.94M	$11.94M
YoY Change	-27.43%	20.24%	20.24%
SHAREHOLDERS EQUITY
Retained Earnings	-$135.4M	-$136.5M
YoY Change	-3.15%	-2.54%
Common Stock	$1.014M	$1.014M
YoY Change	0.26%	0.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$306.8K	$306.8K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$30.12M	$28.96M	$28.96M
YoY Change
Total Liabilities & Shareholders Equity	$46.50M	$40.90M	$40.90M
YoY Change	-3.34%	16.35%	16.35%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2023
OPERATING ACTIVITIES
Net Income	$1.142M	-$1.229M	$3.562M
YoY Change	273.28%	-150.61%	-55.7%
Depreciation, Depletion And Amortization	$328.3K	$344.1K	$1.278M
YoY Change	10.8%	14.38%	5.67%
Cash From Operating Activities	-$2.710M	$2.969M	$3.339M
YoY Change	386.05%	84.93%	-48.7%
INVESTING ACTIVITIES
Capital Expenditures		$536.2K	$5.737M
YoY Change		-302.97%	-1250.61%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$536.2K	-$5.737M
YoY Change		102.97%	1050.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$3.957M	-12.50M	$1.702M
YoY Change	-66.74%	13166.16%	-355.15%
NET CHANGE
Cash From Operating Activities	-$2.710M	2.969M	$3.339M
Cash From Investing Activities		-536.2K	-$5.737M
Cash From Financing Activities	$3.957M	-12.50M	$1.702M
Net Change In Cash	$1.247M	-10.07M	-$695.7K
YoY Change	-88.91%	-907.56%	-113.02%
FREE CASH FLOW
Cash From Operating Activities	-$2.710M	$2.969M	$3.339M
Capital Expenditures		$536.2K	$5.737M
Free Cash Flow	-$2.710M	$2.432M	-$2.398M
YoY Change	485.38%	30.11%	-134.22%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001053369
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent		usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
CY2023	us-gaap	Interest Income Expense After Provision For Loan Loss InterestIncomeExpenseAfterProvisionForLoanLoss		usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1		usd
CY2023	ELTP	Supplemental Noncash Amounts Of Lease Liabilities Arising From Obtaining Right Of Use Assets SupplementalNoncashAmountsOfLeaseLiabilitiesArisingFromObtainingRightOfUseAssets		usd
CY2023	us-gaap	Dilutive Securities DilutiveSecurities		usd
CY2022	us-gaap	Dilutive Securities DilutiveSecurities		usd
CY2023	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1		usd
CY2022	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1		usd
CY2022	ELTP	Finitelived Intangible Assets Reductions FinitelivedIntangibleAssetsReductions		usd
CY2023Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent		usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo		usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree		usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2023	ELTP	Foreign Income Tax Expense Benefit Continuing Operationsnet ForeignIncomeTaxExpenseBenefitContinuingOperationsnet		usd
CY2023	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-15697
CY2023	dei	Entity Registrant Name EntityRegistrantName	ELITE PHARMACEUTICALS, INC.
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-3542636
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	165 LUDLOW AVENUE
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	NORTHVALE
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07647
CY2023	dei	City Area Code CityAreaCode	(201)
CY2023	dei	Local Phone Number LocalPhoneNumber	750-2646
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	ELTP
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Public Float EntityPublicFloat	40556603	usd
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1013915081	shares
CY2023	dei	Auditor Name AuditorName	Buchbinder Tunick & Company LLP
CY2023	dei	Auditor Location AuditorLocation	Little Falls, New Jersey 07424
CY2023	dei	Auditor Firm AuditorFirmId	6189
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7832247	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8535357	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3094549	usd
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3057913	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	9550716	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	6741170	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1032785	usd
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	526949	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	21510297	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	18861389	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14586335	usd
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13348565	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10426158	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5952992	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6341228	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6634035	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13062	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1031884	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2171821	usd
CY2022Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2171821	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	412434	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	405039	usd
CY2023Q1	us-gaap	Security Deposit SecurityDeposit	21018	usd
CY2022Q1	us-gaap	Security Deposit SecurityDeposit	91738	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	433452	usd
CY2022Q1	us-gaap	Other Assets OtherAssets	496777	usd
CY2023Q1	us-gaap	Assets Assets	40896018	usd
CY2022Q1	us-gaap	Assets Assets	35148898	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2446810	usd
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1430985	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5047726	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4693142	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13333	usd
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13333	usd
CY2023Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	110822	usd
CY2022Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	100822	usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent	200032	usd
CY2022Q1	us-gaap	Loans Payable Current LoansPayableCurrent	253006	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	14914	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	202953	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7833637	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6694241	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	18890	usd
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	32226	usd
CY2023Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1029018	usd
CY2022Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1139848	usd
CY2023Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	2532502	usd
CY2022Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	249046	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	835893	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	521711	usd
CY2022Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	936837	usd
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	38780	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4102121	usd
CY2022Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3232630	usd
CY2023Q1	us-gaap	Liabilities Liabilities	11935758	usd
CY2022Q1	us-gaap	Liabilities Liabilities	9926871	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1445000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1445000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1014015081	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1013915081	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1011381988	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1011281988	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	1014019	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	1011385	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164750980	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164577227	usd
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	100000	shares
CY2022Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	100000	shares
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	306841	usd
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	306841	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-136497898	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-140059744	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	28960260	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	25222027	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40896018	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35148898	usd
CY2023	ELTP	Revenue From Manufacturing Fees RevenueFromManufacturingFees	29187573	usd
CY2022	ELTP	Revenue From Manufacturing Fees RevenueFromManufacturingFees	26951863	usd
CY2023	ELTP	Revenue From Licensing Fees RevenueFromLicensingFees	4967541	usd
CY2022	ELTP	Revenue From Licensing Fees RevenueFromLicensingFees	5310254	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34155114	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32262117	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	17561093	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	17466763	usd
CY2023	us-gaap	Gross Profit GrossProfit	16594021	usd
CY2022	us-gaap	Gross Profit GrossProfit	14795354	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6200163	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4051349	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5122272	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4464003	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39325	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14353	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-292807	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1263452	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1194939	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	12918019	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	9724644	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	3676002	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	5070710	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	415126	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1425409	usd
CY2023	us-gaap	Interest Expense InterestExpense	1112707	usd
CY2022	us-gaap	Interest Expense InterestExpense	191816	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1000000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	7453	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	126	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	309872	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1233719	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3985874	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6304429	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	424028	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1736437	usd
CY2022	us-gaap	Interest Income Expense After Provision For Loan Loss InterestIncomeExpenseAfterProvisionForLoanLoss	857379	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	3561846	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	8898245	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1012911346	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1010607713	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1012911346	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1010607713	shares
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	16151929	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	8898245	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14353	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	157500	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	25222027	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	25222027	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	3561846	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	39325	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	60000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	77062	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	28960260	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	28960260	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	3561846	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	8898245	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1277622	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1209119	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	67061	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	225590	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-292807	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	415126	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1425409	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2171821	usd
CY2023	ELTP	Accrued Compensation Non Cash AccruedCompensationNonCash	540000	usd
CY2022	ELTP	Accrued Compensation Non Cash AccruedCompensationNonCash	767122	usd
CY2023	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	39325	usd
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	14353	usd
CY2023	ELTP	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	803	usd
CY2022	ELTP	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	1152	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	36636	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-438463	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2809546	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1728268	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	435116	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-209796	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1336566	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	314214	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-13336	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-13332	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-67566	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-230910	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3338704	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6508314	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5736618	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	498566	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5736618	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-498566	usd
CY2023	us-gaap	Repayments Of First Mortgage Bond RepaymentsOfFirstMortgageBond	115000	usd
CY2022	us-gaap	Repayments Of First Mortgage Bond RepaymentsOfFirstMortgageBond	110000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	12240111	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	14438985	usd
CY2023	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	381675	usd
CY2022	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	557133	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1702199	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-667133	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-695715	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5342615	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8940396	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3597781	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8244681	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8940396	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1098537	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	177636	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	424028	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	244124	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	137062	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	157500	usd
CY2022	ELTP	Supplemental Noncash Amounts Of Lease Liabilities Arising From Obtaining Right Of Use Assets SupplementalNoncashAmountsOfLeaseLiabilitiesArisingFromObtainingRightOfUseAssets	1042800	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7832247	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8535357	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	412434	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	405039	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8244681	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8940396	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34155114	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32262117	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	412434	usd
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	405039	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-292807	usd
CY2023	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1000000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3561846	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	8898245	usd
CY2023	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-415126	usd
CY2022	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-1425409	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	3146720	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	7472836	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1012911346	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1010607713	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1012911346	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1010607713	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	5407075	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	521711	usd
CY2022Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	936837	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2352330	usd
CY2022Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	159808	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1791311	usd
CY2022Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1203204	usd
CY2022Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	5378158	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	9550716	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	6741170	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25012493	usd
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19301557	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14586335	usd
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13348565	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10426158	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5952992	usd
CY2023	us-gaap	Depreciation Depreciation	1237770	usd
CY2022	us-gaap	Depreciation Depreciation	1194939	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6634035	usd
CY2023	ELTP	Finitelived Intangible Assets Impairment FinitelivedIntangibleAssetsImpairment	-292807	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6341228	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6634035	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6634035	usd
CY2023Q1	us-gaap	Loans Payable LoansPayable	259611	usd
CY2022Q1	us-gaap	Loans Payable LoansPayable	502052	usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent	200032	usd
CY2022Q1	us-gaap	Loans Payable Current LoansPayableCurrent	253006	usd
CY2023Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	2532502	usd
CY2022Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	249046	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	1013874	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	62845	usd
CY2023Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	4125000	usd
CY2022Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	3625000	usd
CY2023Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	414989	usd
CY2022Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	414989	usd
CY2023Q1	ELTP	Accrued Consultant Contract Fees AccruedConsultantContractFees	193333	usd
CY2022Q1	ELTP	Accrued Consultant Contract Fees AccruedConsultantContractFees	153333	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	125000	usd
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	140000	usd
CY2023Q1	ELTP	Accrued Director Dues AccruedDirectorDues	70000	usd
CY2022Q1	ELTP	Accrued Director Dues AccruedDirectorDues	90000	usd
CY2022Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	143000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	119404	usd
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	126820	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5047726	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4693142	usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	32223	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	usd
CY2023Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	18890	usd
CY2022Q1	us-gaap	Deferred Revenue DeferredRevenue	45559	usd
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	usd
CY2022Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	32226	usd
CY2023	ELTP	Operating Lease Renewal Term OperatingLeaseRenewalTerm	The 135 Ludlow Ave. modified lease includes an initial term, which expired on December 31, 2016 with two tenant renewal options of five years each, at the sole discretion of the Company. On June 22, 2016, the Company exercised the first of these renewal options, with such option including a term that begins on January 1, 2017 and expires on December 31, 2021. On June 30, 2021, the Company exercised the second of the renewal options, with such option including a term that begins on January 1, 2022 and expires on December 31, 2026.
CY2023Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2020Q4	ELTP	Operating Lease Renewal Term OperatingLeaseRenewalTerm	The Pompano Office includes a 3 month abatement from November 2020 through February 2021 and has a term of three years, ending on October 31, 2023
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13062	usd
CY2023Q1	ELTP	Operating Lease Assets OperatingLeaseAssets	13062	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	14914	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	14914	usd
CY2023	us-gaap	Payments For Rent PaymentsForRent	58248	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	229563	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	15214	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15214	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	300	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	14914	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y7M6D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	13903960	usd
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	13903960	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.1521
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.1521
CY2023Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y1M6D
CY2022Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y1M6D
CY2023	ELTP	Common Stock Issued During Period Shares CommonStockIssuedDuringPeriodShares	2633093	shares
CY2022	ELTP	Common Stock Issued During Period Shares CommonStockIssuedDuringPeriodShares	2105236	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5900000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.13
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y8M12D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	500000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.05
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	750000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5650000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.14
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y9M18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	15530000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.03
CY2023	ELTP	Sharebased Compensation Arrangement By Sharebased Payment Award Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAverageRemainingContractualTermGranted	P10Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15370000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.07
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4182000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.14
CY2023	ELTP	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableOutstandingWeightedAverageRemainingContractualTerm	P2Y2M12D
CY2023Q1	ELTP	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.03
CY2022Q1	ELTP	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.03
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	205340	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	784577	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1160715	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2171821	usd
CY2023	ELTP	Federal Benefit Of Net Operating Loss Carryforward FederalBenefitOfNetOperatingLossCarryforward	-784577	usd
CY2022	ELTP	Federal Benefit Of Net Operating Loss Carryforward FederalBenefitOfNetOperatingLossCarryforward	-1160715	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	424028	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	435384	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	424028	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1736437	usd
CY2022	ELTP	Foreign Income Tax Expense Benefit Continuing Operationsnet ForeignIncomeTaxExpenseBenefitContinuingOperationsnet	857379	usd
CY2022	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	857379	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.90	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.90	pure
CY2022	ELTP	Income Tax Benefit By Judgement IncomeTaxBenefitByJudgement	2200000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	0.0	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	400000	usd

Files In Submission

Name	View Source	Status
0001493152-23-022936-index-headers.html	Edgar Link	pending
0001493152-23-022936-index.html	Edgar Link	pending
0001493152-23-022936.txt	Edgar Link	pending
0001493152-23-022936-xbrl.zip	Edgar Link	pending
eltp-20230331.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
eltp-20230331_def.xml	Edgar Link	unprocessable
eltp-20230331_cal.xml	Edgar Link	unprocessable
eltp-20230331_lab.xml	Edgar Link	unprocessable
eltp-20230331_pre.xml	Edgar Link	unprocessable
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2023 Q2 Form 10-K Financial Statement

#000149315223022936 Filed on June 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2023 Q2 Form 10-K Financial Statement

#000149315223022936 Filed on June 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp